Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL503017 | 0.78 | KDM4E (0.38) | L3MBTL1ADRA2CCAPN1BRD4MAPK1 | |
| SCHEMBL25937459 | 0.77 | CAPN1 (0.47) | L3MBTL1ADRA2CCAPN1BRD4MAPK1 | |
| SCHEMBL9634672 | 0.77 | L3MBTL1 (0.38) | L3MBTL1 | |
| SCHEMBL11464542 | 0.77 | ADRA2C (0.33) | L3MBTL1ADRA2CMAPK1 | |
| SCHEMBL25937418 | 0.70 | CAPN1 (0.41) | L3MBTL1CAPN1BRD4 | |
| Dioxane SCHEMBL9486523 | 0.69 | KDM4E (0.36) | L3MBTL1BRD4 | |
| SCHEMBL11999052 | 0.67 | ADRA2C (0.48) | L3MBTL1ADRA2CBRD4MAPK1 | |
| SCHEMBL10501254 | 0.67 | KDM4E (0.35) | L3MBTL1 | |
| SCHEMBL9193310 | 0.66 | CRBN (0.33) | L3MBTL1 | |
| SCHEMBL25404748 | 0.65 | F2 (0.41) | HDAC6ADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080131420-A1 | METHODS AND COMPOSITIONS FOR TREATING MUCOSAL INFLAMMATION | ACCENTIA, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| WO-2008008494-A2 | METHODS AND COMPOSITIONS FOR TREATING MUCOSAL INFLAMMATION | ACCENTIA BIOPHARMACEUTICALS, INC. (US) | 2008-01-17 | — | — | WO | disclosed |
| EP-0744171-B1 | DENTAL COMPOSITION FOR HYPERSENSITIVE DENTIN | SUN MEDICAL CO LTD (JP) | 2003-09-03 | — | — | EP | disclosed |
| EP-0721773-B1 | Dental composition for relieving dentin hypersensitivity | SUN MEDICAL CO LTD (JP) | 2002-03-27 | — | — | EP | disclosed |
| US-5879663-A | Dental composition for dentin hypersensitivity | SUN MEDICAL CO., LTD. (JP) | 1999-03-09 | — | — | US | disclosed |
| US-5766328-A | Dental composition for relieving dentin hypersensitivity | SUN MEDICAL CO., LTD. (JP) | 1998-06-16 | — | — | US | disclosed |
| EP-0744171-A1 | DENTAL COMPOSITION FOR HYPERSENSITIVE DENTIN | SUN MEDICAL CO., LTD. (JP) | 1996-11-27 | — | — | EP | disclosed |
| EP-0721773-A2 | Dental composition for relieving dentin hypersensitivity | SUN MEDICAL CO., LTD. (JP) | 1996-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080131420-A1 | METHODS AND COMPOSITIONS FOR TREATING MUCOSAL INFLAMMATION | MMP8, MUC1, MPO | HDAC6 190/4885L3MBTL1 4869/4885ADRA2C 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.